Protalix BioTherapeutics (PLX) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.17 --0%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $25.77 million versus the consensus estimate of $23.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Increasing unusual put option volume: LION GPN FJET BTG PURR JCI AVGX KBH VTRS
- Increasing unusual call option volume: FEZ VRNS NICE MIR OPTU BZFD IRDM METC ADTN STUB
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
